Literature DB >> 9658598

Corticosteroid treatment in active Crohn's disease.

J Belaiche1, E Louis.   

Abstract

Despite recent improvements in the management of Crohn's disease, steroids are still the most efficacious treatment in flare ups of the disease. However they have significant side effects and are only effective in the short term. There is no consensus regarding initial dose or duration of corticotherapy. With 1 mg/Kg a day of oral prednisolone given for 3 to 7 weeks, 92% of the patients achieve clinical remission. Topical acting oral corticosteroids such as budesonide seem to represent an important therapeutic advance due to their better tolerance. The promising results of budesonide in mild and moderate flare ups need to be confirmed and its indication in severe disease beside high dose prednisolone has to be clarified.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9658598

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  2 in total

1.  Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn's Disease: A Retrospective Claims Database Analysis.

Authors:  Ryan C Ungaro; Jenny Griffith; Viviana Garcia-Horton; Aolin Wang; Raymond K Cross
Journal:  Crohns Colitis 360       Date:  2022-08-04

2.  Dramatic improvement of severe acne pustolosa after adalimumab in a patient with ulcerative colitis.

Authors:  Antonio Rispo; Dario Musto; Nicola Imperatore; Anna Testa; Matilde Rea; Fabiana Castiglione
Journal:  Clin Case Rep       Date:  2016-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.